Published in Clin Cancer Res on September 01, 2005
Retracted Oral carcinogenesis and oral cancer chemoprevention: a review. Patholog Res Int (2011) 1.82
Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol (2008) 1.42
Oral premalignancy: new methods of detection and treatment. Curr Oncol Rep (2006) 1.09
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res (2013) 1.02
Understanding carcinogenesis for fighting oral cancer. J Oncol (2011) 0.94
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Thorac Oncol (2014) 0.93
Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2. Virchows Arch (2009) 0.85
Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy. J Cell Sci Ther (2011) 0.79
GW627368X inhibits proliferation and induces apoptosis in cervical cancer by interfering with EP4/EGFR interactive signaling. Cell Death Dis (2016) 0.77
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Lung cancer. N Engl J Med (2008) 13.49
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res (2005) 5.33
Whole-genome scan, in a complex disease, using 11,245 single-nucleotide polymorphisms: comparison with microsatellites. Am J Hum Genet (2004) 4.76
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA (2004) 4.31
Statins and cancer prevention. Nat Rev Cancer (2005) 4.12
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst (2006) 3.62
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res (2006) 3.34
Retracted The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med (2004) 3.22
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol (2008) 3.16
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) (2011) 2.97
Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res (2004) 2.95
Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci (2003) 2.91
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell (2003) 2.71
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst (2006) 2.61
Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol (2005) 2.48
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 2.42
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.41
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst (2009) 2.34
Effects of cigarette smoke on the human oral mucosal transcriptome. Cancer Prev Res (Phila) (2010) 2.30
Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem (2002) 2.29
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov (2012) 2.23
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 2.21
Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) (2011) 2.09
Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res (Phila) (2009) 2.06
Effects of tobacco smoke on gene expression and cellular pathways in a cellular model of oral leukoplakia. Cancer Prev Res (Phila) (2008) 2.04
Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol (2005) 1.98
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol (2007) 1.97
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol (2007) 1.95
Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol (2010) 1.94
The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels. Cancer Prev Res (Phila) (2011) 1.85
The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A (2003) 1.84
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.79
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol (2003) 1.78
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol (2009) 1.74
Mortality risk from squamous cell skin cancer. J Clin Oncol (2005) 1.74
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res (Phila) (2008) 1.71
Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue. Cancer (2014) 1.71
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res (2008) 1.68
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst (2014) 1.67
Science peels the onion of selenium effects on prostate carcinogenesis. J Natl Cancer Inst (2004) 1.66
Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasia. Cancer Prev Res (Phila) (2012) 1.66
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol (2009) 1.66
Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res (2010) 1.66
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst (2007) 1.65
Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res (2013) 1.65
Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol Cell Proteomics (2005) 1.63
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol (2007) 1.61
Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem (2003) 1.60
COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. Semin Oncol (2004) 1.59
High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) (2009) 1.59
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res (2002) 1.59
Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol (2003) 1.59
Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest (2013) 1.58
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) (2009) 1.57
Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance. Clin Cancer Res (2010) 1.55
Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res (2005) 1.55
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res (2006) 1.55
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol (2005) 1.54
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol (2013) 1.54
The Scherrer equation versus the 'Debye-Scherrer equation'. Nat Nanotechnol (2011) 1.53
Adenoma recurrences after resection of colorectal carcinoma: results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study. Ann Surg Oncol (2003) 1.53
Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 1.52